E S Jaffe

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi The pathology of NK-cell lymphomas and leukemias
    Victor E Nava
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Adv Anat Pathol 12:27-34. 2005
  2. ncbi Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Mod Pathol 26:S71-87. 2013
  3. ncbi Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology
    E S Jaffe
    Hematopathology Section, Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1500, USA
    Mod Pathol 14:219-28. 2001
  4. ncbi Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Hematology Am Soc Hematol Educ Program 2011:506-14. 2011
  5. ncbi The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
    Elias Campo
    Hematopathology Section, Department of Anatomic Pathology, Hospital Clinic, Institute of Biomedical Research August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Blood 117:5019-32. 2011
  6. ncbi Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification
    E S Jaffe
    Hematopathology Section, National Cancer Institute, Bethesda, MD, USA
    Ann Oncol 11:17-21. 2000
  7. ncbi Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology
    Elaine S Jaffe
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892 1500, USA
    Mod Pathol 17:131-5. 2004
  8. ncbi Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 112:4384-99. 2008
  9. ncbi Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
    Richard F Little
    Center for Cancer Research (CCR, National Cancer Institute (NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:4653-9. 2003
  10. ncbi The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010

Detail Information

Publications117 found, 100 shown here

  1. ncbi The pathology of NK-cell lymphomas and leukemias
    Victor E Nava
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Adv Anat Pathol 12:27-34. 2005
    ..Benign proliferations of NK cells can be seen in association with viral infection. The disease formerly referred to as blastic NK-cell lymphoma is now considered to be a malignancy derived from a dendritic cell precursor...
  2. ncbi Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Mod Pathol 26:S71-87. 2013
    ..New data are emerging on the molecular pathogenesis of T-cell and NK-cell lymphoma, but most tumor types remain poorly characterized...
  3. ncbi Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology
    E S Jaffe
    Hematopathology Section, Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1500, USA
    Mod Pathol 14:219-28. 2001
    ..Conversely, most cases of Hodgkin's-like ALCL have proved to be more closely related to true Hodgkin's disease, and are unrelated to ALCL...
  4. ncbi Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Hematology Am Soc Hematol Educ Program 2011:506-14. 2011
    ....
  5. ncbi The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
    Elias Campo
    Hematopathology Section, Department of Anatomic Pathology, Hospital Clinic, Institute of Biomedical Research August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Blood 117:5019-32. 2011
    ..The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities, is reviewed. These new observations chart a course for future research in the field...
  6. ncbi Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification
    E S Jaffe
    Hematopathology Section, National Cancer Institute, Bethesda, MD, USA
    Ann Oncol 11:17-21. 2000
    ..The classification of cutaneous lymphomas has been controversial. The EORTC has proposed that conventional classification schemes are not suitable for cutaneous lymphomas, and that a unique classification system is required...
  7. ncbi Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology
    Elaine S Jaffe
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892 1500, USA
    Mod Pathol 17:131-5. 2004
    ..Ancillary studies are often required, and the Association recommends that immunophenotypic and genotypic information be integrated into the final report, to the extent possible...
  8. ncbi Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 112:4384-99. 2008
    ..In addition, accurate and precise classification of disease entities facilitates the discovery of the molecular basis of lymphoid neoplasms in the basic science laboratory...
  9. ncbi Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
    Richard F Little
    Center for Cancer Research (CCR, National Cancer Institute (NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:4653-9. 2003
    ..These results suggest that tumor pathogenesis is responsible for the improved outcome of ARLs in the era of HAART...
  10. ncbi The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010
    ..However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death. This trial was registered at www.clinicaltrials.gov as NCT000019253...
  11. ncbi Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
    Wyndham H Wilson
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 99:2685-93. 2002
    ..Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens. Dynamic dose adjustment may overcome inadequate drug concentrations, particularly in younger patients, and compensate for increased drug clearance over time...
  12. ncbi Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features
    M W Beaty
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Surg Pathol 25:1111-20. 2001
    ..The relationship of the plaque-like lesions to LYG remains uncertain. Whereas some cases of LYG regress spontaneously, most require therapy...
  13. ncbi Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray
    Hongbin Zha
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lab Invest 84:235-44. 2004
    ..The activation of the Akt/Bad pathway provides further evidence of prosurvival signals in FL, independent of Bcl-2 alone. These data suggest that nodal FL represents a single disease with a final common biochemical pathway...
  14. ncbi Angiocentric immunoproliferative lesions: a molecular analysis of eight cases
    L J Medeiros
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Hum Pathol 22:1150-7. 1991
    ..These findings further emphasize the unique clinicopathologic aspects of AILs and may also be useful diagnostically in the differential diagnosis of lymphoproliferative disorders...
  15. ncbi T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells
    Megan S Lim
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Surg Pathol 26:1458-66. 2002
    ..A subset of THRLBCL may be related to nodular lymphocyte predominance Hodgkin's lymphoma. A small percentage show features closely resembling classic Hodgkin's lymphoma and could be considered a variant of grey zone lymphoma...
  16. ncbi The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 346:1937-47. 2002
    ..CONCLUSIONS: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma...
  17. ncbi Stromal gene signatures in large-B-cell lymphomas
    G Lenz
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 359:2313-23. 2008
    ..Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear...
  18. ncbi In situ localization of follicular lymphoma: description and analysis by laser capture microdissection
    Peijie Cong
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 99:3376-82. 2002
    ..These findings provide insight into the pathophysiology of early FL, and illustrate the utility of immunohistochemistry for early diagnosis...
  19. ncbi Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma...
  20. ncbi Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis
    Leticia Quintanilla-Martinez
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:3181-7. 2003
    ....
  21. ncbi Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR
    Kathryn A Rizzo
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1500, USA
    Mod Pathol 23:866-73. 2010
    ..Overall the incidence of genetic aberrations in marginal zone lymphomas in the pediatric and young adult population is low, but the aberrations seen are similar to those seen in the adult population...
  22. ncbi Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
    ..The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL...
  23. ncbi Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 113:6069-76. 2009
    ..This trial is registered with http://www.ClinicalTrials.gov under identifier NCT00057902...
  24. ncbi gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study
    J R Toro
    Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1908, USA
    Arch Dermatol 136:1024-32. 2000
    ..Only a few cases of primary gamma delta cutaneous T-cell lymphoma (CTCL) have been reported. We encountered 3 cases of this rare condition...
  25. ncbi Burkitt's/Burkitt's-like lymphoma presenting as bacterial sinusitis in two HIV-infected children
    M R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 1863, USA
    AIDS Patient Care STDS 15:453-8. 2001
    ..Burkitt's/Burkitt's-like lymphoma in the paranasal sinuses has not been previously described in HIV-infected children...
  26. ncbi The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
    S E Straus
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Blood 98:194-200. 2001
    ..These data implicate a role for Fas-mediated apoptosis in preventing B-cell and T-cell lymphomas. Inherited defects in receptor-mediated lymphocyte apoptosis represent a newly appreciated risk factor for lymphomas...
  27. ncbi HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis
    R F Little
    HIV and AIDS Malignancy Branch, National Cancer Institute, Bldg 10, Room 10S255, 9000 Rockville Pike, Bethesda, MD 20892, USA
    JAMA 285:1880-5. 2001
    ..Successful strategies for achieving favorable outcomes currently exist with available therapies...
  28. ncbi A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn
    P H Levine
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 80:662-6. 1999
    ....
  29. ncbi Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis--CT and US features
    N A Avila
    Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1182, USA
    Radiology 212:257-63. 1999
    ..To describe the imaging findings in patients with autoimmune lymphoproliferative syndrome (ALPS) and to relate the findings to the clinical and genetic features of this recently recognized syndrome...
  30. ncbi Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study
    R E Curtis
    Division of Cancer Epidemiology, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
    Blood 94:2208-16. 1999
    ..0% +/- 2.9% and 22% +/- 17.9%, respectively. We conclude that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD...
  31. ncbi A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
    ....
  32. ncbi Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society
    B E Favara
    National Institutes of Health, Rocky Mountain Laboratories, Laboratory of Persistent Viral Diseases, Hamilton, MT 59840 2999, USA
    Med Pediatr Oncol 29:157-66. 1997
    ..Guidelines for distinguishing the exceedingly rare malignant diseases of histiocytes from large cell lymphomas through the use of a battery of special studies are provided...
  33. ncbi Cells of the marginal zone--origins, function and neoplasia
    H C Morse
    Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, Building 7, Room 304, 7 Center Drive MSC 0760, Bethesda, MD 20892 0760, USA
    Leuk Res 25:169-78. 2001
    ..Only splenic MZL are seen in mice. A reduced threshold for triggering to proliferation may predispose the marginal zone B cell to neoplasia with mutations in genes regulating apoptosis playing a leading role...
  34. ncbi Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis
    M C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 89:1341-8. 1997
    ..Fas gene mutations account for impaired lymphocyte apoptosis in only a subset of patients with ALPS...
  35. ncbi Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)
    V Koneti Rao
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-1888, USA
    Am J Hematol 81:81-5. 2006
    ....
  36. ncbi Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma
    Christian Gulmann
    National Cancer Institute--Food and Drug Administration Clinical Proteomics Program, Laboratory of Pathology, Bethesda, MD 20892, USA
    Clin Cancer Res 11:5847-55. 2005
    ..Proteomic end points should be incorporated in larger, multicenter trials to validate the clinical utility of these protein microarray findings...
  37. ncbi Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging
    Athos D Patsalides
    Department of Diagnostic Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bldg 10, Room 1C660, 9000 Rockville Pike, Bethesda, MD 20892 1182, USA
    Radiology 237:265-73. 2005
    ..To retrospectively evaluate the magnetic resonance (MR) imaging features of lymphomatoid granulomatosis in the brain...
  38. ncbi Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis
    Andrew L Feldman
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Lancet Oncol 6:435-7. 2005
  39. ncbi Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop
    Joao B Oliveira
    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:e35-40. 2010
    ..It is hoped that harmonizing the diagnosis and classification of ALPS will foster collaborative research and better understanding of the pathogenesis of autoimmune cytopenias and B-cell lymphomas...
  40. ncbi Automatic classification of lymphoma images with transform-based global features
    Nikita V Orlov
    National Institute on Aging, NIH, Baltimore, MD 21224, USA
    IEEE Trans Inf Technol Biomed 14:1003-13. 2010
    ..The best signal (98%-99% on earlier unseen images) was found for the HE, H, and E channels of the H&E data set...
  41. ncbi Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Sandeep S Dave
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    N Engl J Med 351:2159-69. 2004
    ..CONCLUSIONS: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis...
  42. ncbi Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis
    Antonio Martinez
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 28:849-58. 2004
    ..PTCL following CLL should be distinguished from typical Richter syndrome, which it can mimic clinically...
  43. ncbi IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma
    Sonam Prakash
    Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 30:585-92. 2006
    ..IgD positivity may represent an additional useful marker in the diagnosis of NLPHL...
  44. ncbi Hodgkin lymphoma: an update on its biology with new insights into classification
    Haresh Mani
    Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Lymphoma Myeloma 9:206-16. 2009
    ..Nodular sclerosis HL might also be related to primary mediastinal B-cell lymphoma and mediastinal gray-zone lymphomas. We present an update on the pathobiology of HL and discuss these biologic and clinical differences in this review...
  45. ncbi Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome
    Kennichi C Dowdell
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1888, USA
    Blood 115:5164-9. 2010
    ..These findings also highlight the potential role for somatic mutations in the pathogenesis of nonmalignant and/or autoimmune hematologic conditions in adults and children...
  46. ncbi IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma
    Katherine R Calvo
    Hematopathology Section, Laboratory of Pathology LP, NIH Clinical Center, Department of Laboratory Medicine, 10 Center Drive, Bldg 10 2C306, Bethesda, MD 20892 1500, USA
    Blood 112:3818-26. 2008
    ..These findings suggest IL-4, Erk, and possibly Stat-6 may play a role in the biology of FL and may serve as targets for future therapies...
  47. ncbi Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker
    Antonio Martinez
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Surg Pathol 32:1190-200. 2008
    ..These results suggest an important role for IRF8 during germinal center B-cell development and in related lymphomas, and provide a new diagnostic marker helpful in distinguishing B-cell non-Hodgkin lymphoma subtypes...
  48. ncbi Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    Wyndham H Wilson
    Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 26:2717-24. 2008
    ....
  49. ncbi Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome
    J Keith Killian
    Genetics Branch, Laboratory of Pathology, NIH National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 69:758-64. 2009
    ..Analysis of the DMT profile is consistent with a pervasive epigenomic remodeling process in FL that affects predominantly nonlymphoid genes...
  50. ncbi Mycosis fungoides and Sézary syndrome
    Sam T Hwang
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
    Lancet 371:945-57. 2008
    ....
  51. ncbi Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
    Ola Landgren
    Division of Cancer Epidemiology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Blood 113:4992-5001. 2009
    ..Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial...
  52. ncbi Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone
    Andrew L Feldman
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892 1500, USA
    Blood 111:5433-9. 2008
    ..1 was seen in all cases tested. These results provide evidence for a common clonal origin of FL and H/DC neoplasms when occurring in the same patient, and suggest that lineage plasticity may occur in mature lymphoid neoplasms...
  53. ncbi Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study
    Michie Hisada
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 8008, Bethesda, MD 20892 7201, USA
    J Natl Cancer Inst 99:215-22. 2007
    ..The available evidence is conflicting, with most risk estimates based on sparse numbers. To our knowledge, no study has evaluated cause-specific mortality in patients with hairy cell leukemia...
  54. ncbi Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS
    Robert J Biggar
    Viral Epidemiology Branch, National Cancer Institute, 6120 Executive Blvd, Rm EPS 7074, Bethesda, MD 20852, USA
    Blood 108:3786-91. 2006
    ..With more severe immunosuppression, nodular sclerosing HL becomes infrequent, explaining the higher proportion of mixed cellularity HL found in PWAs. Pathogenesis implications are discussed...
  55. ncbi Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
    Georg Lenz
    Metabolism Branch, Biometric Research Branch, Center for Information Technology, and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:13520-5. 2008
    ..Together, these data provide genetic evidence that the DLBCL subtypes are distinct diseases that use different oncogenic pathways...
  56. ncbi Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
    John E Janik
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:3355-7. 2004
    ..Serum sIL-2R levels were elevated in both patients with recurrent disease...
  57. ncbi Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin
    Andrew L Feldman
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Lancet Oncol 5:248-50. 2004
  58. ncbi Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma
    Jorge R Toro
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7231, USA
    Blood 101:3407-12. 2003
    ..067). No other prognostic factors were identified as having a notable association with outcome in this subgroup. TCR delta 1 expression in primary cutaneous lymphomas is an independent prognostic factor associated with decreased survival...
  59. ncbi Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin
    Lei Yao
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 12N226 MSC 1907, 10 Center Drive, Bethesda, MD, USA
    Cancer Immunol Immunother 51:358-66. 2002
    ....
  60. ncbi Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus
    Eric A Engels
    Viral Epidemiology Branch, Division of Cancer and Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892, USA
    Mod Pathol 16:424-9. 2003
    ..We conclude that Kaposi's sarcoma-associated herpesvirus is present in some immunoblastic lymphomas in persons with AIDS-associated Kaposi's sarcoma...
  61. ncbi Bethesda proposals for classification of lymphoid neoplasms in mice
    Herbert C Morse
    Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0760, USA
    Blood 100:246-58. 2002
    ..The classification should facilitate communications about mouse models of human lymphoid diseases...
  62. ncbi Peripheral T-cell lymphomas expressing CD30 and CD15
    Todd S Barry
    Hematopathology Section, Laboratory of Pathology, National Cancer Intitute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 27:1513-22. 2003
    ..In some PTCL cases, the overlap with classic HL can be striking, and combined immunophenotypic and molecular studies are often necessary to confirm the diagnosis...
  63. ncbi Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA
    Mod Pathol 15:255-63. 2002
    ..Lymphomatoid granulomatosis is common in the lung but is rarely seen in the midline facial structures...
  64. ncbi Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
    Richard L Piekarz
    Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute, National Institutes of Health, Bethesda, USA
    J Clin Oncol 27:5410-7. 2009
    ..The median duration of response was 13.7 months. CONCLUSION The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL...
  65. ncbi A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease
    M C Sneller
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Invest 90:334-41. 1992
    ..The clinical and immunological features of this syndrome resemble the lymphoproliferative/autoimmune disease seen in lpr and gld mice...
  66. ncbi Sjögren's syndrome-like illness associated with the acquired immunodeficiency syndrome-related complex
    R C Ulirsch
    Hematopathology Section, National Cancer Institute, Bethesda, MD 20892
    Hum Pathol 18:1063-8. 1987
    ..Patients with such features should be studied for HIV antibodies and other evidence of autoimmune phenomena in order to define more precisely the nature of this new Sjögren's-like illness...
  67. ncbi Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy
    J M Pluda
    National Cancer Institute, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
    Ann Intern Med 113:276-82. 1990
    ..As improved therapies for the treatment of HIV infection and its complications result in prolonged survival, non-Hodgkin lymphoma may become an increasingly significant problem...
  68. ncbi Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms
    T Yano
    Hematopathology Section, National Cancer Institute, Bethesda, MD 20892
    Blood 82:1813-9. 1993
    ....
  69. ncbi Chemokine gene expression and clonal analysis of B cells in tissues involved by lymphoid interstitial pneumonitis from HIV-infected pediatric patients
    J Teruya-Feldstein
    Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mod Pathol 14:929-36. 2001
    ..In addition, LIP may represent an early stage of MALT lymphoma or an immunologic response to a chronic antigenic stimulus that may provide a milieu or microenvironment for the evolution of a monoclonal B-cell population...
  70. ncbi High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
    Upendra Hegde
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD 20892-1868, USA
    Blood 105:496-502. 2005
    ..Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry...
  71. ncbi CD5+ follicular lymphoma: a clinicopathologic study of three cases
    Todd S Barry
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Clin Pathol 118:589-98. 2002
    ..These cases highlight the difficulty classifying these lymphomas by flow cytometric studies alone and emphasize the importance of recognizing FL in the differential diagnosis of CD5+ B-cell lymphomas...
  72. ncbi Gall bladder and extrahepatic bile duct lymphomas: clinicopathological observations and biological implications
    Haresh Mani
    The Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 34:1277-86. 2010
    ..31%). In conclusion, primary lymphomas of the gall bladder and extrahepatic bile ducts show a broad spectrum of disease types, but in many respects mirror the spectrum of primary lymphomas of the gastrointestinal tract...
  73. ncbi Marginal zone B-cell lymphoma in children and young adults
    Lekidelu Taddesse-Heath
    Hemopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Am J Surg Pathol 27:522-31. 2003
    ..We conclude that EMZL in children and young adults are similar to EMZL of mucosa-associated lymphoma tissue occurring in older patients. However, pediatric NMZL appear to have distinctive clinical and histologic features...
  74. ncbi Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease
    Girish Venkataraman
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 34:589-94. 2010
    ..Given the central role of defective Fas signaling in ALPS, histiocytes may be yet another lineage at risk for neoplastic transformation secondary to a block in apoptosis...
  75. ncbi Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma
    Katherine R Calvo
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Adv Anat Pathol 11:227-38. 2004
    ....
  76. ncbi Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome
    Irina Maric
    Hematopathology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Am J Surg Pathol 29:903-11. 2005
    ..It remains to be determined if some cases of apparently sporadic SHML may be associated with heritable defects in Fas-mediated apoptosis...
  77. ncbi Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression
    Haipeng Shao
    Laboratory of Pathology and the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 34:1425-35. 2010
    ..Our results suggest that IgA plasmacytomas may represent a distinct form of extramedullary plasmacytoma characterized by younger age at presentation, frequent lymph node involvement, and low risk of progression to plasma cell myeloma...
  78. ncbi Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia
    J Teruya-Feldstein
    Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 93:2463-70. 1999
    ..These results provide evidence of high level chemokine expression in HD tissues and suggest that chemokines may play an important role in the recruitment of inflammatory cell infiltrates into tissues involved by HD...
  79. ncbi Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis
    L J Medeiros
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Arch Pathol Lab Med 117:279-83. 1993
    ..Thus, we suggest that the lymphocytosis results from a poorly defined immunoregulatory disorder, related to the presence of thymoma, and perhaps secondary thymic hormone imbalance...
  80. ncbi Kaposi's sarcoma in human T-cell leukemia virus type I-associated adult T-cell leukemia
    S J Greenberg
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Blood 76:971-6. 1990
    ..Recognition of the similarities and differences between HTLV-I and HIV infections may provide insights concerning the angiopathogenesis of KS...
  81. ncbi Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression
    U Lopatin
    Laboratory of Clinical Investigation, Clinical Research Training Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Blood 97:3161-70. 2001
    ..Nonetheless, in vitro studies showed no influence of IL-10 on the survival of CD4(-)CD8(-) T cells. Overexpression of IL-10 in patients with inherited apoptotic defects is strongly associated with the overt manifestations of ALPS...
  82. ncbi Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall
    X Yao
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA
    Mod Pathol 14:105-10. 2001
    ..Moreover, cases with ambiguous phenotypes may require genotypic studies for precise lineage assignment...
  83. ncbi Histopathology of Hodgkin's lymphoma
    Franziska C Eberle
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer J 15:129-37. 2009
    ..We present an update on the histopathological features of Hodgkin's lymphoma and the immunohistochemical tools available for diagnosis in the clinical setting...
  84. ncbi Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
    Martina Rudelius
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 108:1668-76. 2006
    ..One possible mechanism of activation is loss of PTEN expression. These data suggest that PI3K/Akt inhibitors may be effective in the treatment of Akt-activated MCL...
  85. ncbi Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
    Lluis Colomo
    Hematopathology Section, Laboratory of Pathology, and Department of Hematology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Surg Pathol 28:736-47. 2004
    ..In conclusion, DLBCLs with plasmablastic differentiation are a heterogeneous group of neoplasms with different clinicopathological characteristics that may correspond to different entities...
  86. ncbi Periodic fever with atypical dyshidrosis--quiz case
    Elektra J Papadopoulos
    National Institutes of Health, Bethesda, MD, USA
    Arch Dermatol 140:479-84. 2004
  87. ncbi Immunoguided laser assisted microdissection techniques for DNA methylation analysis of archival tissue specimens
    Franziska C Eberle
    Hematopathology Section, National Cancer Institute, National Institutes of Health, 8717 Grovemont Circle, Bethesda, MD 20892, USA
    J Mol Diagn 12:394-401. 2010
    ..7%; P < 0.05). These results demonstrate the validity and utility of the herein described protocol, which allows the application of ILAM for large-scale genomic and epigenetic analyses of archival tissue specimens...
  88. ncbi Mature T-cell and NK-cell lymphomas in the pediatric age group
    Elaine S Jaffe
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1500, USA
    Am J Clin Pathol 122:S110-21. 2004
    ..This early component of the immune system might be targeted more often in pediatric hematologic malignant neoplasms, whereas tumors of the more mature adaptive immune system are more rare in children...
  89. ncbi IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas
    Alexandra Valera
    Hematopathology Section, Laboratory of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Surg Pathol 34:1686-94. 2010
    ..The oncogenic activation of MYC in these lymphomas may be an important pathogenetic element associated with EBV infection...
  90. ncbi An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells
    Cem Akin
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1881, USA
    Am J Clin Pathol 118:242-7. 2002
    ....
  91. ncbi The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma/Leukemia Molecular Profiling Project, National Cancer Institute/NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
    ..We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy...
  92. ncbi Spectrum of AIDS-associated malignant disorders
    J J Goedert
    Viral Epidemiology Branch, National Cancer Institute, Rockville, MD, USA
    Lancet 351:1833-9. 1998
    ..To clarify which types of cancer result from AIDS, we compared the cancer experiences of people with AIDS with those of the general population by matching population-based cancer and AIDS registries in the USA and Puerto Rico...
  93. ncbi Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas
    W H Wilson
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 16:2345-51. 1998
    ..To assess the efficacy and maximum dose-intensity of a new topoisomerase I (topo I)-targeting agent, 9-aminocamptothecin (9-AC), in patients with relapsed or refractory lymphomas...
  94. ncbi Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6
    Y Aoki
    Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Blood 93:4034-43. 1999
    ..Thus, vIL-6 is a multifunctional cytokine that promotes hematopoiesis, plasmacytosis, and angiogenesis. Through these functions, vIL-6 may play an important role in the pathogenesis of certain KSHV-associated disorders...
  95. ncbi Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease
    J Setsuda
    Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Pathol 155:257-65. 1999
    ....
  96. ncbi Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
    J I Cohen
    Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1500, USA
    Ann Oncol 20:1472-82. 2009
    ..Design: To better define the pathogenesis, classification, and treatment of these disorders, participants from Asia, The Americas, Europe, and Australia presented clinical and experimental data at an international meeting...
  97. ncbi NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia
    A D Steinberg
    National Institutes of Health, Bethesda, MD 20892
    Ann Intern Med 108:575-84. 1988
    ..The rest usually go into a sustained remission. Current treatment with corticosteroid and immunosuppressive agents is unsatisfactory, especially because of late immunosuppression and predisposition to infections...
  98. ncbi Human T-cell lymphotropic virus type I and adult T-cell leukemia/lymphoma outside Japan and the Caribbean Basin
    P H Levine
    Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892
    Yale J Biol Med 61:215-22. 1988
    ..A registry for ATLL cases is suggested, to assist in the identification of risk factors for this disease and, at the same time, improve case definitions and early diagnosis...
  99. ncbi Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases
    Laurence Lamant
    INSERM, U 563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Haematologica 95:449-55. 2010
    ..Skin involvement is frequent in ALK-positive anaplastic large cell lymphomas. The role of an insect bite as a triggering event has been postulated but not well documented...
  100. ncbi Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
    Ken H Young
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, University of of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, USA
    Blood 112:3088-98. 2008
    ..This study shows the prognostic importance of mutations in the TP53 DNA-binding domains in patients with DLBCL...
  101. ncbi Unusual immunophenotype of CD8+ T cells in familial hemophagocytic lymphohistiocytosis
    Nitin J Karandikar
    Department of Pathology, The University of Texas Southwestern Medical Center at Dallas, 75390 9072, USA
    Blood 104:2007-9. 2004
    ..This case provides an instructive example of uncontrolled reactive proliferation of CD8+ T cells in FHL, resulting in atypical morphology and unusual immunophenotypic features that might suggest malignancy in other clinical settings...